INVO Fertility Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39701 INVO Fertility, Inc.(Exact Name of Registrant as Specified in its Charter) (978) 878-9505(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of August 14, 2026, the Registrant had 2,506,969 shares of common stock outstanding. INVO FERTILITY, INC. FORM 10-QFOR THE QUARTERLY PERIOD ENDED JUNE 30, 2026 TABLE OF CONTENTS 1.Financial Statements (Unaudited):4Consolidated Balance Sheet as of June 30, 2026 (Unaudited) and December 31, 20254Consolidated Statements of Operations for the three and six months ended June 30, 2026 and 2025(Unaudited)5Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2026 and2025 (Unaudited)6Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025 (Unaudited)7Notes to the Consolidated Financial Statements82.Management’s Discussion and Analysis of Financial Condition and Results of Operations303.Quantitative and Qualitative Disclosures about Market Risks414.Controls and Procedures41 1.Legal Proceedings421A.Risk Factors422.Unregistered Sales of Equity Securities and Use of Proceeds423.Defaults Upon Senior Securities424.Mine Safety Disclosure425.Other Information426.Exhibits43Signatures44 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions ofSection 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934,as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,”“expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these termsor other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates, andprojections about our company, are not guarantees of future results or performance, and involve substantial risks and uncertainty. Wemay not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. Actual results or eventscould differ materially from the plans, intentions, and expectations disclosed in these forward-looking statements. Our business andour forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertaintiesinherent in our statements regarding the following: ●Our financial condition and need for additional capital; ●Our limited operating history and a history of net operating losses, and we depend on continued access to capital and clinicrevenue growth to fund our operations;●The competitiveness of the fertility and ART services industry;●The dependence of our growth strategy on identifying and successfully completing and integrating fertility clinic acquisition;●Our dependence on key executives, physicians, embryologists, and clinical personnel;●Risks associated with operating certain of our fertility clinics as joint ventur